NASDAQ:GDTC CytoMed Therapeutics (GDTC) Stock Price, News & Analysis $0.97 0.00 (-0.10%) Closing price 12:20 PM EasternExtended Trading$0.97 +0.00 (+0.10%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About CytoMed Therapeutics Stock (NASDAQ:GDTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytoMed Therapeutics alerts:Sign Up Key Stats Today's Range$0.96▼$0.9650-Day Range$0.88▼$1.3252-Week Range$0.68▼$3.68Volume185 shsAverage Volume11,848 shsMarket Capitalization$11.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore. Read More CytoMed Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreGDTC MarketRank™: CytoMed Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 767th out of 838 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCytoMed Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCytoMed Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CytoMed Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCytoMed Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.32% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 2.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytoMed Therapeutics has recently decreased by 17.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoMed Therapeutics does not currently pay a dividend.Dividend GrowthCytoMed Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for GDTC on MarketBeat in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $128,800.00 in company stock, which represents 1.1236% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, CytoMed Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $128,800.00 in company stock and sold $0.00 in company stock.Percentage Held by Institutions0.04% of the stock of CytoMed Therapeutics is held by institutions.Read more about CytoMed Therapeutics' insider trading history. Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GDTC Stock News HeadlinesCytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBankJune 23, 2026 | tipranks.comCytoMed Therapeutics Shareholders Approve All Resolutions at May 22 AGMJune 3, 2026 | tipranks.comOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warning for AI investors - and a specific prediction about what the number-one investment of the next decade will be. Green started his career on Wall Street four decades ago and retired in his 40s. He believes a major shift in the AI trade is coming - and that most investors won't hear about it until it's too late.July 22 at 1:00 AM | The Oxford Club (Ad)CytoMed Renames Subsidiary to Drive Asian and International ExpansionMay 11, 2026 | tipranks.comCytoMed Therapeutics Sets May 22, 2026 AGM With Expanded Share-Issuance Mandate on the TableApril 14, 2026 | tipranks.comCytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia ExpansionMarch 31, 2026 | tipranks.comCytoMed Therapeutics Refutes Misleading Claims, Confirms Ongoing First-in-Human TrialJanuary 28, 2026 | tipranks.comCytoMed Therapeutics Addresses Inaccurate Claims About Its Research and Clinical ProgressJanuary 28, 2026 | quiverquant.comQSee More Headlines GDTC Stock Analysis - Frequently Asked Questions How have GDTC shares performed this year? CytoMed Therapeutics' stock was trading at $1.3350 on January 1st, 2026. Since then, GDTC shares have decreased by 27.4% and is now trading at $0.9690. When did CytoMed Therapeutics IPO? CytoMed Therapeutics (GDTC) raised $11 million in an initial public offering (IPO) on Wednesday, April 12th 2023. The company issued 2,412,369 shares at $4.00-$5.00 per share. How do I buy shares of CytoMed Therapeutics? Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoMed Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Today7/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 GDTC's financial health is in the Green zone, according to TradeSmith. GDTC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GDTC CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployeesN/AYear Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio5.17 Quick Ratio5.17 Sales & Book Value Annual Sales$250 thousand Price / Sales45.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book2.15Miscellaneous Outstanding Shares11,830,000Free FloatN/AMarket Cap$11.46 million OptionableNot Optionable Beta0.01 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:GDTC) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | SponsoredIt all happens tonight.Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...Trade Thirsty | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
